Crohn's Disease Market is expected to Hit USD 21.8 billion by 2033 | Major Companies - Biogen, Merck & Co, Novartis AG, Janssen Biotech, Inc, Takeda Pharmaceuticals

DataM Intelligence has unveiled its latest report on the "Crohn's Disease Market Size 2026" delivering powerful insights into key trends, future growth opportunities, and evolving market challenges. Designed to empower smarter decision-making, the report equips businesses with the strategic intelligence needed to stay ahead in a competitive landscape. By blending robust qualitative analysis with data-driven quantitative research, DataM Intelligence offers a well-rounded perspective that helps organizations decode complex market dynamics, unlock new avenues for growth, and seize emerging opportunities in an ever-evolving global market.

Unlock Strategic Partnerships in the Growing Crohn's Disease Market-Connect with Key Industry Leaders Today: https://www.datamintelligence.com/partner-identification-enquiry/crohns-disease-market?sz

The Global Crohn's Disease Market size reached USD 14.6 billion in 2025 and is expected to reach USD 21.8 billion by 2033, growing at a CAGR of 6.5% during the forecast period 2026 to 2033.

The Crohn's Disease Market refers to the global ecosystem of products, therapies, diagnostics, and healthcare services focused on the prevention, diagnosis, treatment, and management of Crohn's disease, a chronic inflammatory bowel disorder. The market includes biologics, immunomodulators, corticosteroids, biosimilars, targeted therapies, diagnostic tools, and surgical interventions. Growth is driven by increasing disease prevalence, rising awareness, advancements in biologic treatments, personalized medicine approaches, and ongoing research into innovative therapies improving long-term patient outcomes.

Download Free Sample Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/crohns-disease-market?sz

Recent Industry Developments: United States

✅ April 2026: The U.S. FDA approved expanded use of STELARA (ustekinumab) for pediatric patients aged 2 years and older with moderate-to-severe Crohn's disease, increasing treatment options in pediatric inflammatory bowel disease.

✅ March 2026: Increased commercialization momentum for ustekinumab biosimilars continued in the U.S., strengthening competition in Crohn's disease biologics and supporting lower treatment costs.

✅ January 2026: Growing adoption of advanced biologics and targeted therapies accelerated in the U.S. Crohn's disease market, driven by regulatory approvals and expansion of maintenance therapies for moderate-to-severe disease.

Recent Industry Developments: Japan

✅ April 2026: Japan approved additional ustekinumab biosimilar products, expanding affordable biologic access for autoimmune conditions including Crohn's disease and increasing biosimilar competition.

✅ March 2026: Celltrion Healthcare Japan entered a strategic partnership with CMIC Group to expand biosimilar adoption and improve supply stability in Japan, supporting wider access to therapies used for Crohn's disease management.

✅ January 2026: Japan's Crohn's disease treatment landscape continued shifting toward biologics and biosimilars, supported by regulatory focus on improving affordability and increasing availability of advanced therapies.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/crohns-disease-market?sz

List of the Key Players in the Crohn's Disease Market:

Biogen
Merck & Co
Novartis AG
Janssen Biotech, Inc
Takeda Pharmaceuticals
UCB S.A
AbbVie
Prometheus Laboratories

How Does Market Research Work in the Crohn's Disease Market?

Market research for the Crohn's Disease Market involves systematic data collection and analysis to understand industry trends, customer behavior, and competitive dynamics. It includes primary research such as surveys and interviews, and secondary research from reports, databases, and publications. Analysts evaluate market size, growth drivers, challenges, and opportunities using qualitative and quantitative methods. Insights are validated through expert opinions and forecasting models, enabling businesses to make strategic decisions, identify target segments, and gain a competitive advantage in a rapidly evolving market.

Latest Mergers and Acquisitions of Crohn's Disease Market:

✅ April 2026: Eli Lilly acquires Kelonia Therapeutics (up to US$7 billion)
➠ Eli Lilly announced the acquisition of Kelonia Therapeutics for up to US$7 billion, strengthening its biotechnology portfolio.
➠ Although Kelonia is focused on oncology, Lilly stated the deal aligns with its broader expansion strategy across inflammatory diseases and IBD-related therapies, including Crohn's disease.
➠ The move reflects aggressive M&A activity by companies building immune-mediated disease pipelines.

✅ January 2026: Boehringer Ingelheim signs >€1 billion licensing deal with Simcere Pharma for IBD candidate
➠ Boehringer Ingelheim entered a global licensing agreement for SIM0709, an experimental treatment targeting inflammatory bowel disease pathways.
➠ Deal terms include €42 million upfront plus up to €1.016 billion in milestone payments.
➠ The agreement expands Boehringer's presence in autoimmune and Crohn's-related therapeutic development.

✅ January 2026: Eli Lilly enters advanced talks to acquire Ventyx Biosciences (>US$1 billion)
➠ Reports indicated Eli Lilly was negotiating to acquire Ventyx Biosciences for over US$1 billion.
➠ Ventyx develops therapies for Crohn's disease, ulcerative colitis, and other inflammatory bowel diseases, making the potential acquisition strategically important for the Crohn's market.
➠ The deal highlighted increasing competition among pharma firms to secure next-generation IBD assets.

Segments Covered in the Crohn's Disease Market 2026:

By Type: Ileocolitis, Ileitits, Gastroduodenal Crohn's, Jejunoileitis.

By Drug Class: Anti-inflammatory Drugs, Immunosuppressors, Biologics, Antibiotics, Pain relievers, Others.

By Route of Administration: Injectable, Oral.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Regional Analysis of the Crohn's Disease Market:

⇥ North America: Leads the market due to advanced infrastructure, strong R&D investments, and early adoption of new technologies.

⇥ Europe: Shows steady growth supported by strict regulations and increasing focus on sustainability initiatives.

⇥ Asia-Pacific: Fastest-growing region driven by rapid industrialization, urbanization, and rising consumer demand in emerging economies.

⇥ Latin America: Experiences moderate growth with expansion in industrial and commercial sectors.

⇥ Middle East & Africa: Gradual market growth supported by increasing investments and improving economic conditions.

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=crohns-disease-market

Key Benefits of the Report:

⏩ Comprehensive Market Insights: Gain a deep understanding of market size, trends, and structure.

⏩ Accurate Forecasting: Access reliable future projections to support long-term planning.

⏩ Competitive Analysis: Identify key players, strategies, and positioning in the market.

⏩ Data-Driven Decisions: Make informed business choices backed by verified data.

⏩ Opportunity Identification: Discover emerging trends and untapped growth areas.

⏩ Risk Mitigation: Reduce uncertainties with thorough market evaluation.

⏩ Customer Insights: Understand consumer behavior, preferences, and buying patterns.

⏩ Strategic Planning Support: Align business strategies with market realities.

⏩ Time & Cost Efficiency: Save resources by leveraging ready-to-use research.

⏩ Customization & Expert Validation: Benefit from tailored insights and industry expert analysis.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Crohn's Disease Market in 2025?
◆ What is the projected growth rate of the Crohn's Disease Market through 2033?
◆ Who are the key players in the Crohn's Disease Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Fabian
Email: fabian@datamintelligence.com
Phone USA: +1 877-441-4866
Phone UK: +44 161-870-5507
Website:https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.